Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.68 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riccardi C SCHEMBL22704770 | 0.81 | NR1H2 (1.00) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Riccardi C SCHEMBL29606810 | 0.81 | NR1H2 (1.00) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Riccardin D SCHEMBL30335734 | 0.74 | NR1H2 (0.73) | NR1H2NR1H3PTGS1PTGS2POLB | |
| SCHEMBL29623815 | 0.72 | NR1H2 (0.78) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Riccardi F SCHEMBL29829924 | 0.68 | NR1H2 (0.74) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Riccardin A SCHEMBL31069022 | 0.67 | NR1H2 (0.72) | NR1H2NR1H3PTGS1PTGS2POLB | |
| SCHEMBL21582170 | 0.65 | MIF (0.47) | NR1H2NR1H3PTGS1PTGS2HSP90AA1 | |
| SCHEMBL784291 | 0.62 | MAOB (0.59) | NR1H2NR1H3PTGS1PTGS2POLB | |
| SCHEMBL21582169 | 0.62 | MAOB (0.47) | NR1H2NR1H3PTGS1PTGS2POLB | |
| SCHEMBL29350443 | 0.62 | MAOB (0.47) | NR1H2NR1H3PTGS1PTGS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024108201-A2 | CANNABIGEROLIC ACID (CBGA) AND CANNABIGEROL (CBG) DERIVED PRODUCTS AND METHODS OF USE | Bazelet Health Systems, Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240082270-A1 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | BAZELET HEALTH SYSTEMS INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC | 2022-11-17 | — | — | US | disclosed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | NR1H2 4268/4885NR1H3 3801/4885PTGS1 859/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | NR1H2 618/4885NR1H3 729/4885PTGS1 262/4885 |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | PRKG2, PRKG1, CIT | NR1H2 4268/4885NR1H3 3801/4885PTGS1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.